Thiel Capital
Thiel Capital is a company that specializes in investment management services.
Business Model:
Revenue: $16M
Employees: 51-200
Rankings
Detailed Thiel Capital Information
Geographic Data
Address: 1 Letterman Dr Ste 400
City: San Francisco
State: CA
Zip: 94129
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
3,936,609Website Global Rank
3,070Website Monthly Traffic
Twitter Followers
Description
Thiel Capital is an investment firm founded by Peter Thiel. Located in the Presidio of San Francisco, Thiel Capital provides strategic and operational support for Peter’s many investment initiatives and entrepreneurial endeavors. Related organizations include Clarium, Founders Fund, Mithril, Valar Ventures, and The Thiel Foundation.
Contact Phone:
+14154411460
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2020 | Ready | Seed Round | 1.2M |
| 6/2021 | Ex-human | Pre Seed Round | 550k |
| 4/2021 | Angiex | Series B | 25M |
| 11/2020 | ATAI Life Sciences | Series C | 0 |
| 8/2022 | 28 by Evie | Seed Round | 0 |
| 3/2021 | ATAI Life Sciences | Series D | 0 |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 10/2022 | Alloy Therapeutics | Series D | 42M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 2/2020 | EnClear Therapies | Series A | 0 |
| 3/2019 | EnClear Therapies | Seed Round | 2M |
| 2/2022 | Regent | Equity | 18M |
| 4/2020 | ATAI Life Sciences | Convertible Note | 25M |
| 12/2019 | Chemomab | Series C | 20M |
| 11/2017 | Immunochina | Series B | 7.5M |
| 5/2021 | Bullish Global | Venture Round | 300M |
| 9/2022 | Vienna Hypertext | Seed Round | - |
| 8/2018 | Spark Neuro | Series A | 13.5M |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 10/2017 | 3T Biosciences | Seed Round | 12M |
| 1/2018 | Invicta Medical | Series B | 0 |
| 7/2016 | Invicta Medical | Series A | 0 |
| 12/2020 | Rational Vaccines | Series A | 10M |
| 1/2020 | Advano | Series A | 18.5M |
| 5/2018 | Terminal | Series A | 10M |
| 7/2017 | Angiex | Series A | 3M |
| 11/2021 | Mynaric | Post-IPO Equity | 0 |
| 7/2022 | Inflection Points | Seed Round | 0 |
| 7/2022 | Inflection Points | Seed Round | 0 |
| 2/2022 | Regent | Venture Round | 0 |
| 11/2021 | Mynaric | Post-IPO Equity | 0 |
| 6/2021 | Ex-human | Pre Seed Round | 0 |
| 5/2021 | Bullish Global | Venture Round | 0 |
| 4/2021 | Angiex | Series B | 0 |
| 3/2021 | ATAI Life Sciences | Series D | 0 |
| 12/2020 | Rational Vaccines | Series A | 0 |
| 11/2020 | ATAI Life Sciences | Series C | 0 |
| 8/2020 | Ready | Seed Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
